

CURRICULUM VITAE

Name : **Vangelis G. Manolopoulos**
Address (work): Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Dragana Campus, 68100 Alexandroupolis, GREECE
Tel / Fax: +30-25510-30523
GSM: +30-69777-11119
e-mail: emanolop@med.duth.gr
Place of birth: Athens, Greece

EDUCATION

1979-1984 University of Patras Applied Sciences School, Patras, Greece
Bachelor Degree in Biology
1987-1991 University of Patras Medical School, Patras, Greece
Doctorate (Ph.D) in Pharmacology

SCIENTIFIC POSITIONS

04/09 - **Associate Professor**, Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, **Greece**
01/03 - 12/08 **Assistant Professor**, as above
12/98 - 01/03 **Lecturer**, as above
09/95 - 11/98 **Research Associate**, Laboratory of Physiology, Medical School, Katholieke Universiteit Leuven, **Belgium**
01/92 - 08/95 **Postdoctoral Fellow**, Laboratory of Cell Biology, Department of Medicine, University of Wisconsin Medical School, Milwaukee, WI, **USA**
10/89 - 07/90 **Visiting Scientist**, Department of Clinical Pharmacology, University of Groningen Medical School, Groningen, **The Netherlands**
01/87 - 12/91 **Research Assistant**, Department of Pharmacology, University of Patras Medical School, Patras, **Greece**
01/85 - 12/86 **Research Assistant**, Experimental Embryology Laboratory, University of Patras Biology School, Patras, **Greece**

ADMINISTRATIVE POSITIONS

05/03 - 09/08: **Director**, Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, **Greece**
08/02 – 09/08: **Director**, Laboratory of Clinical Pharmacology and Therapeutic Drug Monitoring Unit, Academic General Hospital of Alexandroupolis, **Greece**

MEMBERSHIP IN SCIENTIFIC COMMITTEES

- Member of the **Scientific Council** of Academic Hospital of Alexandroupolis (since 2005)
- Member of the **Drug Committee** of the Academic Hospital of Alexandroupolis (since 2005)
- Member (2005-2009) και Head (2009-2011) of the **Clinical Trials Committee and the Ethical Board** of the Academic General Hospital of Alexandroupolis
- Member of the **Internal Evaluation Committee** of the Democritus University of Thrace Medical School (2008-2009)

MEMBERSHIP IN PROFESSIONAL SOCIETIES (Selection)

- **European Society for Pharmacogenomics and Theranostics** (Vice President for Education and Courses, 2011-2015)
- **European Association of Clinical Pharmacology and Therapeutics** (Representative of Greece to the Board 2005-2007 and 2007-2011)
- **American Society for Pharmacology and Experimental Therapeutics (ASPET)**
- **European Atherosclerosis Society (EAS)**
- **European Society for Pharmacogenomics and Theranostics** (founding member, Vice President for education)
- **International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)**
- **Greek Society for Basic and Clinical Pharmacology** (Elected Treasurer 2003-2007, General Secretary of the Board 2007-2009, member of the Council 2009-2013)
- **Greek Atherosclerosis Society**: Member (2007-2009) και Head (2009-2011) of the Working Group on the Study of Pathophysiology of Atherosclerosis of the Greek Atherosclerosis Society
- **Atherosclerosis Society of North Greece**

MEMBERSHIP IN JOURNAL EDITORIAL BOARDS

- **Pharmacogenomics** (since April 2011)
- **Drug Metabolism and Drug Interactions** (since Nov 2010)
- **Hellenic Journal of Atherosclerosis** (since Sep 2010)

CURRENT FUNDING

1. Participation in a European Consortium consisting of 12 labs from 7 countries called EU-PACT (EUropean Pharmacogenomics of Anticoagulant Therapy) which received funding from FP7 thematic line: *Integrating pharmacogenomic approaches into the treatment of cardiovascular disease* for the project ***A pharmacogenomic approach to coumarin anticoagulant therapy***. Total EU funding: 2,5 million euro (230.000 euro for Greece) for 4 years (01/10/08 – 31/09/12). I am the National Coordinator and Principal Investigator for Greece.

2. Principal Investigator of Project titled: «Genetic factors affecting childhood asthma and response of patients to antiasthmatic medication» funded by Greek Health Ministry. Funding: 12.000. Duration: 01/01/10 – 31/12/10.

OTHER FACTS

- Wrote and published in international scientific journals (with Impact Factor) more than 50 articles (original research + reviews)
- Participated (with published abstracts) in more than 60 national international scientific congresses
- Supervises graduate students, technicians, and other research personnel
- Has been invited several times for lectures to meetings in Greece and abroad
- Was an evaluator of Large Scale Integrating Projects submitted to the EE in 1st cycle of Framework Program 7 (FP7) in subjects: α) Pathophysiology of Atherosclerosis β) Vessel remodeling in aneurysmal disease.

- Participated in the EU Health Directorate of DG Research Delegation to New Zealand, 24-28/02/08, led by Mr Stéphane Hogan
- Prepared grant applications to the National Institutes of Health (NIH), the American Heart Association (AHA), the European Union, and Greek funding agencies
- Reviewed manuscripts for publication in several leading *journals* (*Pharmacogenomics, Atherosclerosis, Disease Markers, Pflugers Archiv, Cell Calcium, Endothelium etc*)
- Teaches a 2-semester course in Basic and Clinical Pharmacology and an elective course in Pharmacogenetics to Medical students
- Participated in the research training of Medical Residents and students

CURRENT RESEARCH INTERESTS

- Genetic and epigenetic studies in cardiovascular medicine
- Clinical applications of pharmacogenetics in drug metabolism, cardiovascular disease, diabetes, anticoagulant therapy and psychiatric disease
- Atherosclerosis
- Development of novel antiatherosclerotic, lipid-lowering and antioxidant agents
- Endothelial cell physiology and pathophysiology and anion channel function

SELECTED PUBLICATIONS (*only those appearing in Medline*):

- **52 Publications**
 - **Total impact factor: 171**
 - **Citations : 910 (until Feb 2011)**
 - **H-index : 18**
1. Manolopoulos VG, Ragia G, Tavridou A “Pharmacogenomics of oral antidiabetic treatment: current data and pharmacoepigenomic perspective” *Pharmacogenomics, in press, Aug 2011*.
 2. Manolopoulos VG, Dechairo B, Huriez A, Kuehn A, Llerena A, Van Schaik R, Yeo J, Ragia G, Siest G, “Fifth Santorini conference pharmacogenomics roundtable report: Pharmacogenomics and personalized medicine in clinical practice” *Pharmacogenomics, in press, June 2011*.
 3. Tavridou A, Ragia G, Manolopoulos VG “Emerging targets for the treatment of dyslipidemia” *Current Medicinal Chemistry* 18(6):909-922, 2011.
 4. Squassina A, Artac M, Manolopoulos VG, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Manchia M, Del Zompo M, Patrinos GP. “Translation of genetic knowledge into clinical practice: the expectations and realities of pharmacogenomics and personalized medicine” *Pharmacogenomics* 11(8):1149-1167, 2010.
 5. Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis G, Bougioukas G, Manolopoulos VG. Endothelial nitric oxide synthase gene polymorphisms -786T>C and 894G>T in coronary artery bypass graft surgery patients” *Human Genomics* 4(6):1-9, 2010.
 6. Tavridou A, Efthimiadis A, Efthimiadis I, Manolopoulos VG. “Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia” *Heart & Vessels* 25(4):288-293, 2010.
 7. Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee A-H, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RMF, Wadelius M. “A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives” *Pharmacogenomics* 11(7): 989-1002, 2010.

8. Iordanidou M, Tavridou A, Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, Manolopoulos VG "The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes" *Clinica Chimica Acta* 411:167-171, 2010.
9. Iordanidou M, Tavridou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, Manolopoulos VG "Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians", *Drug and Alcohol Dependence* 108:70-76, 2010.
10. Donnelly MP, Paschou P, Grigorenko E, Gurwitz D, Mehdi SO, Kajuna SLB, Barta C, Kungulilo S, Karoma NJ, Lu R-B, Zhukova OV, Kim J-J, Comas D, Siniscalco M, New M, Li P, Li H, Manolopoulos VG, Speed WC, Rajeevan H, Pakstis AJ, Kidd JR, Kidd KK. "The Distribution and Most Recent Common Ancestor of the 17q21 Inversion in Humans". *American Journal of Human Genetics* 86(2):161-171, 2010.
11. Manolopoulos VG, Ragia G, Tavridou A "Pharmacogenetics of Coumarinic Oral Anticoagulants" *Pharmacogenomics* 11(4): 493-496, 2010.
12. Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis G, Bougioukas G, Manolopoulos VG "Renin-angiotensin system gene polymorphisms in coronary artery bypass graft surgery patients" *Journal of Renin Angiotensin Aldosterone System* 11(2):136-145, 2010.
13. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG, " Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: The case of Greece" *Pharmacogenomics* 10: 43-49, 2009.
14. Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H "Oxidized low-density lipoprotein and arterial function in beta-thalassemia major" *European Journal of Haematology* 82: 477-483, 2009.
15. Tavridou A, Arvanitidis KI, Tiptiri-Kourpeti A, Petridis J, Ragia G, Kyroglou S, Christakidis D, Manolopoulos VG " Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population" *Diabetes Research and Clinical Practice* 84(2): 132-137, 2009.
16. Tavridou A, Manolopoulos VG, "EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors" *Current Pharmaceutical Design* 15(27): 3167-3178, 2009.
17. Manolopoulos VG, Tavridou A, "Drugs targeting atherosclerosis: current and emerging approaches" *Current Pharmaceutical Design* 15(27):3091-3093, 2009.
18. Tavridou A, Manolopoulos VG, "Inhibitors of 5-lipoxygenase activating protein (FLAP) – WO2008030369" *Expert Opinion on Therapeutic Patents*, 19(10): 1473-1476, 2009.
19. van Schie RMF, Wadelius M, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland-van der Zee A-H, "Genotype-guided dosing of coumarin derivatives: the European pharmacogenomics of anticoagulant therapy (EU-PACT) trial design" *Pharmacogenomics* 10: 1287-1295, 2009.
20. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG, "Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulphonylurea oral hypoglycemic agents" *Pharmacogenomics* 10: 1781-1787, 2009.
21. Tavridou A, Manolopoulos VG. "Novel molecules targeting dyslipidemia and atherosclerosis" *Current Medicinal Chemistry* 15 (8): 792-802, 2008.
22. Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekkas E, Kourounakis PN, Charalambos A, Manolopoulos VG, "Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit" *Journal of Cardiovascular Pharmacology* 51(6):573-580, 2008.
23. M Iordanidou, A Tavridou, MV Vasiliadis, KI Arvanitidis, J Petridis, DA Christakidis, V Vargemezis, G Bougioukas, VG Manolopoulos, "The -759 C/T polymorphism of the 5-HT_{2C} receptor is associated with type II diabetes in male and female Caucasians" *Pharmacogenetics & Genomics*, 18 (2):153-159, 2008.
24. A Llerena, G Michel, E Jeannesson, S Wong, VG Manolopoulos, et al. "Third Santorini conference pharmacogenomics workshop report: Pharmacogenomics at the crossroads: What else than good science will be needed for the field to become part of personalized medicine?". *Clinical Chemistry and Laboratory Medicine*, 45: 843-850, 2007.
25. K Arvanitidis, G Ragia, M Iordanidou, S Kyriaki, A Xanthi, A Tavridou and VG Manolopoulos. "Genetic polymorphisms of drug-metabolising enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population". *Fundamental and Clinical Pharmacology*, 21 (4): 419-426, 2007.

26. A Tavridou, G Megaritis, AP Kourounakis, A Charalambous and VG Manolopoulos. "EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate eNOS expression in cultured endothelial cells" *Endothelium*, 14 (4): 239-243, 2007.
27. A Tavridou, L Kaklamanis, A Papalois, AP Kourounakis, EA. Rekka, PN Kourounakis, A Charalambous, VG Manolopoulos, "EP2306, a novel squalene synthase inhibitor, inhibits atherosclerosis in the cholesterol-fed rabbit". *Journal of Pharmacology Experimental Therapeutics*, 323(3): 794-804, 2007.
28. VG Manolopoulos. "Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice". *Clinical Chemistry and Laboratory Medicine*, 45: 801-814, 2007.
29. A Tavridou, L Kaklamanis, G Megaritis, AP Kourounakis, A Papalois, D Roukounas, E. Rekka, PN Kourounakis, A Charalambous, VG Manolopoulos. "Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and atherosclerosis". *European Journal of Pharmacology*, 535: 34-42, 2006.
30. AAK Tentes, SK Markakidis, C Karanikiotis, A Fiska, IK Tentes, VG Manolopoulos, T Dimitriou. "Intra-arterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer". *Langenbeck's Archives of Surgery*, 391: 124-129, 2006.
31. A Tavridou, VG Manolopoulos. "Atorvastatin and simvastatin decrease the uptake of acetylated-low density lipoprotein by human monocytes", *Pharmacology* 73: 102-105, 2005.
32. D Gurwitz, Lunshof J, G Dedoussis, CS Flordellis, U Fuhr, J Kirchheiner, J Licinio, A Llerena, VG Manolopoulos, LJ Sheffield, G Siest, F Torricelli, V Vasiliou, S Wong. "Pharmacogenomics education: International society of pharmacogenomics recommendations for medical, pharmaceutical and health schools deans of education" *Pharmacogenomics Journal*, 5: 221-225, 2005.
33. A Tavridou, VG Manolopoulos. "Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) *in vitro* and *in vivo*" *European Journal of Pharmacology* 505: 213-221, 2004.
34. E Papadimitriou, CR Waters, VG Manolopoulos, BR Unsworth, ME Maragoudakis, PI Lelkes, "Regulation of extracellular matrix remodeling and MMP-2 activation in cultured rat adrenal medullary endothelial cells", *Endothelium* 8: 181-194, 2001.
35. VG Manolopoulos, S Liekens, P Koolwijk, T Voets, E Peters, G Droogmans, PI Lelkes, E. De Clercq, B Nilius, "Inhibition of angiogenesis by blockers of volume-regulated anion channels", *General Pharmacology* 34: 107-116, 2000.
36. SH Suh, R Vennekens, VG Manolopoulos, M Freichel, U Schweig, J Prenen, V Flockerzi, G Droogmans, B Nilius, "Characterization of explanted endothelial cells from mouse aorta: electrophysiology and Ca²⁺-signalling", *Pflügers Archiv European Journal of Physiology* 438: 612-620, 1999.
37. I Mountian, VG Manolopoulos, H De Smedt, JB Parys, L Missiaen, F Wuytack, "Expression patterns of sarco/endoplasmic reticulum Ca²⁺-ATPase and inositol 1,4,5-trisphosphate receptor isoforms in vascular endothelial cells", *Cell Calcium* 25: 371-380, 1999.
38. T Voets, V Manolopoulos, J Eggermont, C Ellory, G Droogmans, B Nilius, "Regulation of swelling-activated chloride current in bovine endothelium by protein tyrosine phosphorylation and G proteins", *Journal of Physiology (London)* 506: 341-352, 1998.
39. VG Manolopoulos, JW Fenton II, PI Lelkes, "The thrombin receptor in adrenal medullary endothelial cells is negatively coupled to adenylyl cyclase through a G_i-protein" *Biochimica Biophysica Acta* 1356: 321-332, 1997.
40. E. Papadimitriou, VG Manolopoulos, GT Hayman, ME Maragoudakis, BR Unsworth, JW Fenton II, PI Lelkes, "Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells", *American Journal of Physiology (Cell Physiology)* 272: C1112-C1122, 1997.
41. VG Manolopoulos, T Voets, PE Declercq, G Droogmans, B Nilius, "Swelling-activated efflux of taurine and other organic osmolytes in endothelial cells", *American Journal of Physiology (Cell Physiology)* 273: C214-C222, 1997.
42. VG Manolopoulos, G Droogmans, B Nilius, "Hypotonicity and thrombin activate taurine efflux in BC₃H1 and C₂C₁₂ myoblasts that is down regulated during differentiation", *Biochemical Biophysical Research Communications* 232: 74-79, 1997.
43. VG Manolopoulos, J Prenen, G Droogmans, B Nilius, "Thrombin potentiates volume-activated chloride currents in pulmonary artery endothelial cells" *Pflügers Archiv European Journal of Physiology* 433:

845-847, 1997.

44. B Nilius, J Eggermont, T Voets, G Buyse, V Manolopoulos, G Droogmans, "Properties of volume-regulated anion channels in mammalian cells", *Progress in Biophysics and Molecular Biology* 68: 69-119, 1997.
45. MD Silverman, VG Manolopoulos, BR Unsworth, PI Lelkes, "Tissue factor expression is differentially modulated by cyclic mechanical strain in various human endothelial cells", *Blood, Coagulation, and Fibrinolysis* 7: 281-288, 1996.
46. S Efthimiopoulos, S Punj, V Manolopoulos, M Pangalos, GP Wang, LM Refolo, NK Robakis, "Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein", *Journal of Neurochemistry* 67: 872-875, 1996.
47. VG Manolopoulos, MM Samet, PI Lelkes, "Regulation of the adenylyl cyclase signaling system in various types of cultured endothelial cells", *Journal of Cellular Biochemistry* 57:590-598, 1995.
48. VG Manolopoulos, J Liu, BR Unsworth, PI Lelkes, "Adenylyl cyclase isoforms are differentially expressed in primary cultures of endothelial cells and whole tissue homogenates from various rat tissues", *Biochemical Biophysical Research Communications* 208: 323-331, 1995.
49. VG Manolopoulos, PI Lelkes, "Cyclic strain and forskolin differentially induce cAMP production in phenotypically diverse endothelial cells", *Biochemical Biophysical Research Communications* 191: 1379-85, 1993.
50. VG Manolopoulos, E Pipili-Synetos, A den Hertog, A Nelemans, "Inositol phosphates formed in rat aorta after α_1 -adrenergic stimulation are inhibited by forskolin", *European Journal of Pharmacology* 207: 29-36, 1991.
51. D Synetos, VG Manolopoulos, D Atlas, E Pipili-Synetos, "A human plasma-derived material with clonidine displacing substance (CDS)-like properties, contracts the isolated rat aorta", *Journal of Autonomic Pharmacology* 11: 343-351, 1991.
52. E Pipili, VG Manolopoulos, JD Catravas, ME Maragoudakis, "Angiotensin converting enzyme activity is present in the endothelium-denuded aorta", *British Journal of Pharmacology* 98: 333-335, 1989.

CHAPTERS IN BOOKS / e-PUBLICATIONS

1. D Gurwitz, VG Manolopoulos, "Personalized Medicine" in *Comprehensive Medicinal Chemistry II* (eds D. Triggle, J Taylor), Volume 1: Global Perspective (Volume editor P.D. Kennewell) Elsevier, Amsterdam, pp. 279-295, 2007.
2. CoA reductase inhibitors (Statins)“ published in July 2006 at the official site of the **International Atherosclerosis Society** (www.athero.org/commentaries/comm550.asp).
3. PI Lelkes, VG Manolopoulos, M Silverman, S Zhang, S Carmiol, BR Unsworth, "On the possible role of endothelial cell heterogeneity in angiogenesis" In: *Molecular, cellular, and clinical aspects of angiogenesis* (ed. Maragoudakis ME), Plenum Press, New York, p.1-17, 1996.
4. PI Lelkes, VG Manolopoulos, D Chick, BR Unsworth, "Endothelial cell heterogeneity and organ-specificity" In: *Angiogenesis: Molecular Biology, Clinical Aspects* (ed. Maragoudakis ME), Plenum Press, New York, p. 15-28, 1994.